

Provided by:



## Rheumatology Case Management 2021-2022

**Rheumatology Case Management 2021-2022 - 10/4/2022**

**October 4, 2022**

**9:00 AM - 10:00 AM**

**Online/ Rheumatology conference room ;5white**

### **Target Audience**

This program has been designed for Internal Medicine - Rheumatology

### **Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Demonstrate improved clinical assessment of patients including the ability to look beyond the rheumatology field when asked to consult on patients in the hospital setting and consistent with CDC guidelines
- 2 Demonstrate improved knowledge and skills to assess and differentiate illnesses that mimic rheumatological diseases as to avoid misdiagnosis and mismanagement
- 3 Demonstrate improved knowledge and skills to understand and incorporate into clinical practice the latest guidelines in therapy of Rheumatological disorders

### **Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Designation of Credit**

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **ABIM MOC:** up to 1 MOC points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**Nurses:** This activity is for 1.00 contact hours.

**Pharmacists:** This activity is not approved for pharmacy contact hours

For more information, please contact

Tina Ferris, John Davis

(215) 294-9347, (215) 662-2792

tina.ferris@uphs.upenn.edu, John.Davis@Pennmedicine.upenn.edu

**Check your transcript online at <https://upenn.cloud-cme.com>**

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support\***

None

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose, we consider relationships of the person involved to include financial relationships of a spouse or partner.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. Any peer reviewer with a potential conflict of interest will recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Chris Derk, MD, MSc	Co-Director	Nothing to disclose - 01/31/2022
Anupama Shahane, MD	Course Director	Nothing to disclose - 03/03/2022
Jonathan Kotzin, MD, PhD	Faculty	Nothing to disclose - 07/07/2022
Joelle Koplun, CRNP	Nurse Planner	Nothing to disclose - 03/03/2022
Naomi Amudala, CRNP	Other Planning Committee Member	Nothing to disclose - 09/02/2022
Joshua F. Baker, MD, MSCE	Other Planning Committee Member	Consulting Fee-Bristol-Myers Squibb (Relationship has ended)   Consulting Fee-Pfizer, Inc. (Relationship has ended) - 12/16/2021
Shubhasree Banerjee, MD	Other Planning Committee Member	Nothing to disclose - 03/04/2022
Marissa Blum, MD, MS	Other Planning Committee Member	Nothing to disclose - 11/22/2021
Ethan Craig, MD, MHS	Other Planning Committee Member	Consulting Fee-Novartis (Advanced Health Media) - 03/03/2022
Jonathan Dunham, MD	Other Planning Committee Member	Nothing to disclose - 01/06/2022
Michael George, MD	Other Planning Committee Member	Consulting Fee-AbbVie, Inc. (Relationship has ended)   Grant or research support-Glaxo Smith Kline - 12/16/2021
Chadwick R Johr, MD	Other Planning Committee	Nothing to disclose - 01/01/2022

	Member	
Sharon L Kolasinski, MD	Other Planning Committee Member	Nothing to disclose - 01/27/2022
Peter A Merkel, MD, MPH	Other Planning Committee Member	Consulting Fee-AbbVie, Inc.   Grant or research support-AbbVie, Inc.   Consulting Fee-Astra Zeneca Pharmaceuticals   Grant or research support-Astra Zeneca Pharmaceuticals   Consulting Fee-Boehringer-Ingelheim   Grant or research support-Boehringer-Ingelheim   Advisor-Chemocentryx   Grant or research support-Chemocentryx (Relationship has ended)   Consulting Fee-CSL Behring (Relationship has ended)   Consulting Fee-Dynacure   Consulting Fee-EMD Serono (Relationship has ended)   Grant or research support-Forbius (Relationship has ended)   Consulting Fee-Genentech (Relationship has ended)   Grant or research support-Genentech (Relationship has ended)   Grant or research support-Eicos (Relationship has ended)   Consulting Fee-Sanofi Genzyme (Relationship has ended)   Grant or research support-Sanofi Genzyme (Relationship has ended)   Consulting Fee-Immagene (Relationship has ended)   Consulting Fee-Janssen Pharmaceuticals (J&J) (Relationship has ended)   Consulting Fee-Kiniksa (Relationship has ended)   Consulting Fee-Kyverna   Consulting Fee-Glaxo Smith Kline   Grant or research support-Glaxo Smith Kline   Consulting Fee-Inflarx GMBH   Grant or research support-Inflarx GMBH   Consulting Fee-Magenta (Relationship has ended)   Consulting Fee-Novartis (Advanced Health Media) (Relationship has ended)   Consulting Fee-Neutrolis (Relationship has ended)   Consulting Fee-Takeda Pharmaceuticals   Grant or research support-Takeda Pharmaceuticals   Consulting Fee-MiroBio   Consulting Fee-Mitsubishi (Relationship has ended)   Consulting Fee-Pfizer, Inc. (Relationship has ended)   Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended)   Consulting Fee-Sparrow   Consulting Fee-Talaris (Relationship has ended) - 02/13/2022
Rennie Rhee, MD, MSCE	Other Planning Committee	Nothing to disclose - 02/12/2022

	Member	
Nora Sandorfi, MD	Other Planning Committee Member	Nothing to disclose - 12/19/2021
Carla Scanzello, MD	Other Planning Committee Member	Nothing to disclose - 01/06/2022
Steffan Schulz, MD	Other Planning Committee Member	Nothing to disclose - 01/24/2022
Preethi Thomas, MD	Other Planning Committee Member	Nothing to disclose - 02/12/2022

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected